Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Mease

Showing results (91-100 of 175) with videos related to

Pageof 18
Sort By:
Rheumatology and Therapy|May 23, 2022
Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 TrialsPhilip Mease, Arthur Kavanaugh, Dafna Gladman, et al.
The Journal of Rheumatology|September 9, 2006
Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritisArthur Kavanaugh, Christian Antoni, Philip Mease, et al.
Annals of the Rheumatic Diseases|March 19, 2011
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trialVibeke Strand, Josef S Smolen, Ronald F van Vollenhoven, et al.
Rheumatology (Oxford, England)|June 27, 2018
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)Alice B Gottlieb, Vibeke Strand, Mitsumasa Kishimoto, et al.
Arthritis and Rheumatism|November 1, 2008
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyEdward Keystone, Désireé van der Heijde, David Mason, et al.
Journal of the American Academy of Dermatology|October 25, 2003
AAD consensus statement on psoriasis therapiesJeffrey P Callen, Gerald G Krueger, Mark Lebwohl, et al.
Arthritis and Rheumatism|April 29, 2008
Measuring health in patients with fibromyalgia: content comparison of questionnaires based on the International Classification of Functioning, Disability and HealthBirgit Prodinger, Alarcos Cieza, David A Williams, et al.
Arthritis Care & Research|March 18, 2015
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled StudyArthur Kavanaugh, Désirée van der Heijde, Anna Beutler, et al.
Rheumatology (Oxford, England)|May 19, 2012
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trialEdward C Keystone, Bernard Combe, Josef Smolen, et al.
Journal of the American Academy of Dermatology|June 5, 2019
Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trialsLourdes Maria Perez-Chada, Alice Bendix Gottlieb, Jeffrey Cohen, et al.
Pageof 18

Showing results (91-100 of 175) with videos related to

Sort By:
Pageof 18
Rheumatology and Therapy|May 23, 2022
Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 TrialsPhilip Mease, Arthur Kavanaugh, Dafna Gladman, et al.
The Journal of Rheumatology|September 9, 2006
Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritisArthur Kavanaugh, Christian Antoni, Philip Mease, et al.
Annals of the Rheumatic Diseases|March 19, 2011
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trialVibeke Strand, Josef S Smolen, Ronald F van Vollenhoven, et al.
Rheumatology (Oxford, England)|June 27, 2018
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)Alice B Gottlieb, Vibeke Strand, Mitsumasa Kishimoto, et al.
Arthritis and Rheumatism|November 1, 2008
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyEdward Keystone, Désireé van der Heijde, David Mason, et al.
Journal of the American Academy of Dermatology|October 25, 2003
AAD consensus statement on psoriasis therapiesJeffrey P Callen, Gerald G Krueger, Mark Lebwohl, et al.
Arthritis and Rheumatism|April 29, 2008
Measuring health in patients with fibromyalgia: content comparison of questionnaires based on the International Classification of Functioning, Disability and HealthBirgit Prodinger, Alarcos Cieza, David A Williams, et al.
Arthritis Care & Research|March 18, 2015
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled StudyArthur Kavanaugh, Désirée van der Heijde, Anna Beutler, et al.
Rheumatology (Oxford, England)|May 19, 2012
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trialEdward C Keystone, Bernard Combe, Josef Smolen, et al.
Journal of the American Academy of Dermatology|June 5, 2019
Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trialsLourdes Maria Perez-Chada, Alice Bendix Gottlieb, Jeffrey Cohen, et al.
Pageof 18